DBD stock forecast, quote, news & analysis
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries... Show more
Diebold Nixdorf (DBD) Stock Analysis: Revenue Growth Meets Margin and Guidance Pressures
Key Takeaways
- Diebold Nixdorf shares have been essentially flat over the trailing 30 days, down roughly 0.6%, consolidating in the low-to-mid $60 range after pulling back from late-July levels near $90.
- Third-quarter 2026 revenue rose about 5% year over year to $994.3 million, with retail revenue up 16%, but GAAP earnings per share declined to $0.19 from $1.11 a year earlier.
- Management lowered its full-year 2026 outlook, citing product mix and raw-material cost pressures, and narrowed revenue guidance to $3.86 billion to $3.90 billion.
- The board authorized a new $250 million share repurchase program, and the company announced a planned global ATM-outsourcing collaboration with Euronet (EEFT).
- Demand drivers remain intact, including retail point-of-sale growth and momentum in the Vynamic Smart Vision AI platform.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated analysis pages.
- To see how automated strategies are positioning across the market, visit Tickeron's Trending AI Robots.
Current Market Snapshot
Diebold Nixdorf shares have traded in a relatively narrow band over the most recent 30-day stretch, ending the period little changed from where they began. The stock has most recently been changing hands near $60, with a market capitalization in the low-$2 billion range and a 52-week range spanning roughly $54 to $92. This sideways action follows a more significant repricing earlier in the quarter, when shares moved down from levels around $90 to the $60 area.
Sentiment remains constructive on a consensus basis, with the sell-side leaning bullish and carrying an average 12-month price target well above recent trading levels. However, near-term positioning has been shaped by margin compression, elevated component costs, and a downward revision to full-year financial guidance, which together have kept the stock in a holding pattern despite continued top-line growth.
Diebold Nixdorf (DBD) Business Overview and Competitive Position
Diebold Nixdorf is a leading global provider of technology and services that connect the digital and physical channels of banking and retail. Operating through its Banking and Retail segments, the company manufactures automated teller machines, cash recyclers, branch automation solutions, and self-service kiosks, while also offering point-of-sale systems, transaction-management software, and an extensive field-services organization. Its DN Series hardware portfolio and Vynamic software suite are complemented by recurring services revenue, which provides a measure of stability across the business.
The company has a presence in more than 100 countries and employs roughly 20,000 people. Investors follow DBD closely because of its scale in financial self-service, its expanding retail footprint, and its ongoing effort to shift toward higher-margin software and services. Competitive strengths include a large installed base, multi-vendor service capabilities, and a growing pipeline of AI-enabled offerings such as Vynamic Smart Vision, which helps retailers reduce shrink and improve store operations.
Recent Developments Driving DBD
Several verified developments have shaped investor sentiment around DBD in recent weeks. The most consequential was the release of third-quarter 2026 results, which showed revenue growth of about 5% to $994.3 million, led by a 16% increase in retail revenue. Gross profit rose modestly, but GAAP net income came in at $7.1 million, and diluted earnings per share fell sharply to $0.19 from $1.11 in the prior-year period.
Alongside the report, the company updated its full-year outlook, narrowing revenue guidance to $3.86 billion to $3.90 billion while lowering its adjusted EBITDA range to $490 million to $510 million and its adjusted EPS range to $4.50 to $4.85. Management attributed the revisions to revenue mix and raw-material cost pressures, particularly memory chips, partially offset by productivity improvements and operating-expense discipline. The company also revised its free cash flow expectations lower, to $190 million to $210 million.
Separately, the board authorized a new $250 million share repurchase program, and the company announced a planned global strategic collaboration with Euronet to develop integrated ATM-outsourcing solutions for financial institutions. In the retail technology space, management indicated that Vynamic Smart Vision AI deployments remain on track to exceed 1,000 by the end of the year, reinforcing a longer-term software and recurring-revenue narrative.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a much broader universe of automated strategies. The platform offers hundreds of bots that trade thousands of tickers, but only the top-performing and most relevant systems are surfaced in this section. These bots vary in strategy, timeframe, and performance metrics, ranging from short-term intraday approaches to longer-horizon swing and trend-following models. Because each bot operates with distinct parameters and risk profiles, users can review historical performance and key statistics before selecting an approach that fits their objectives. For investors seeking a data-driven complement to their own research on names such as Diebold Nixdorf, the Trending AI Robots page offers a convenient way to explore automated trading ideas.
2026 Outlook and What Investors Should Watch
Looking ahead, investors are likely to focus on whether Diebold Nixdorf can translate revenue growth into margin recovery. Key factors include the trajectory of component costs, particularly memory chips, and the company's ability to pass through pricing increases and improve its product mix. The banking segment's deployment timing and the retail segment's strong but lower-margin point-of-sale volumes will remain central to profitability.
Additional areas to monitor include the finalization and execution of the Euronet ATM-outsourcing collaboration, the continued scaling of Smart Vision AI deployments, and progress on the company's operational-excellence and cost-reduction programs. Macroeconomic conditions, trade policy, and currency effects also carry relevance given the company's broad international footprint. The recently authorized buyback program and the direction of full-year free cash flow will provide further signals on capital-allocation discipline as the year concludes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DBD's Indicator enters downward trend
The Aroon Indicator for DBD entered a downward trend on October 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 73 similar instances where the Aroon Indicator formed such a pattern. In 61 of the 73 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DBD as a result. In 35 of 55 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for DBD turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 32 similar instances when the indicator turned negative. In 23 of the 32 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
DBD moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DBD crossed bearishly below the 50-day moving average on October 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in 174 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.963) is normal, around the industry mean (-1.902). P/E Ratio (18.317) is within average values for comparable stocks, (15.583). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.072) among similar stocks. P/S Ratio (0.606) is also within normal values, averaging (70.854).
The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. DBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PackagedSoftware